Google
CANF — CAN FITE BIOPHARMA LTD ADR (Healthcare >> Biotechnology)
CANF FAQ
What is CANF's ROE?
CAN FITE BIOPHARMA LTD ADR reports a Return on Equity (ROE) of -177.15%.
What is CANF's dividend yield?
CAN FITE BIOPHARMA LTD ADR offers a dividend yield of 0.00%.
What is CANF's Deepscope Quality Score?
Deepscope rates CANF's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CANF?
Deepscope's AI Timing Score for CANF is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CANF belong to?
CAN FITE BIOPHARMA LTD ADR is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange.
|
USD 3.09
Price
-0.07
(-2.22%)
Day Change
|
|
|---|
CANF, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
38% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.09 |
| PBV / Sector |
1.45 / 4.63
GOOD
|
| Earning Per Share | -12.02 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.12 M
GREAT
|
| Average 1W Daily Value |
0.12 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:14 |
| Symbol | CANF |
| Name | CAN FITE BIOPHARMA LTD ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 2.14 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8.09 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 26 Ben Gurion Street, Ramat Gan, Israel, 5257346
Phone: 972 3 924 1114
Website: https://www.canfite.com
Sector: Healthcare >> Biotechnology
Description: Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
